Patents by Inventor David Borcherding

David Borcherding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF
    Publication number: 20250197422
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Application
    Filed: March 5, 2025
    Publication date: June 19, 2025
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Patrick Bernardelli, Arielle Genevois Borella, Franck Caussanel, Ingrid Devillers, Eric Nicolai, Franck Slowinski, Fabienne Thompson, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF
    Publication number: 20250197420
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Application
    Filed: March 5, 2025
    Publication date: June 19, 2025
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • INDOLE COMPOUNDS AND METHODS OF USE
    Publication number: 20240279220
    Abstract: The invention relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Application
    Filed: March 1, 2024
    Publication date: August 22, 2024
    Inventors: Junkai Liao, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Hurlbut, David Borcherding, Matthieu Barrague, Timothy Alan Gillespy, Alexandre Gross, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Markus Metz, Anatoly Ruvinsky, Claude Barberis
  • INDOLE COMPOUNDS AND METHODS OF USE
    Publication number: 20240239784
    Abstract: The invention relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Application
    Filed: March 1, 2024
    Publication date: July 18, 2024
    Inventors: Junkai Liao, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Hurlbut, David Borcherding, Matthieu Barrague, Timothy Alan Gillespy, Alexandre Gross, Thaddeus Nieduzak, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Markus Metz, Anatoly Ruvinsky, Michael Kothe
  • Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
    Patent number: 7429595
    Abstract: The present invention is directed to acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4 -diaminocyclohexyl)-purines of the formula where Z is selected from the group consisting of —S(O)2—, and —C(O)—.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: September 30, 2008
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: David Borcherding, Jennifer A. Dumont, Norton P. Peet, Paul S. Wright
  • Pyrazoles as inhibitors of tumor necrosis factor
    Publication number: 20060063796
    Abstract: The present invention provides compounds of Formula (I) and ester prodrugs, pharmaceutically acceptable salts or solvates of such compounds; or ester prodrugs of such salts or solvates; pharmaceutical compositions comprising such compounds, their preparation, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and/or tumor necrosis factor (TNF).
    Type: Application
    Filed: November 1, 2005
    Publication date: March 23, 2006
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: David Borcherding, Alexandre Gross, Patrick Shum, Nicole Willard, Brian Freed
  • Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
    Patent number: 6861524
    Abstract: The present invention is directed to acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines of the formula where Z is selected from the group consisting of —S(O)2—, and —C(O)—.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: March 1, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: David Borcherding, Jennifer A. Dumont, Norton P. Peet, Paul S. Wright
  • Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
    Publication number: 20040248908
    Abstract: The present invention is directed to acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines of the formula 1
    Type: Application
    Filed: October 2, 2003
    Publication date: December 9, 2004
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: David Borcherding, Jennifer A. Dumont, Norton P. Peet, Paul S. Wright
  • Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
    Publication number: 20030069259
    Abstract: The present invention is directed to acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and methods of using the same as antiproliferative agents or to prevent apoptosis.
    Type: Application
    Filed: October 31, 2001
    Publication date: April 10, 2003
    Inventors: David Borcherding, Jennifer A. Dumont, Norton P. Peet, Paul S. Wright